CLNN News and Press, Clene Inc. From 02/12/24

Researchers from ETH Zurich have developed a new magnetic resonance imaging (MRI) technique that can ease multiple sclerosis diagnosis and produce more accurate findings. Led by Emily Baadsvik and Markus Weiger from ETH Zurich’s Institute for Biomedical Engineering, the research team cre...

Clene recently reported new results from the open-label, long-term extension (“LTE”) of the VISIONARY-MS trial, involving participants with stable relapsing Multiple Sclerosis (“MS”) through week 144 (over 2.75 years) after the initial randomization Results from the ...

--News Direct-- Clene Inc (NASDAQ:CLNN) CEO Rob Etherington joined Steve Darling from Proactive to share news regarding the latest findings from the long-term open-label extension (LTE) of the VISIONARY-MS trial. This trial focuses on participants with stable relapsing multiple sclero...

Clene’s (NASDAQ: CLNN) lead drug candidate CNM-Au8 was the subject of two Phase 2a clinical trials, REPAIR-PD and REPAIR-MS, which evaluated the effects of CNM-Au8 on brain energy metabolite levels in participants with diagnoses of idiopathic Parkinson’s Disease (“PD”...

An innovative combination of insights from physics, chemistry, materials science, and biology positions the new nanomedicine CNM-Au8(R) to address neurodegenerative disease, such as ALS, from a new angle The FDA has offered guidance to Clene on CNM-Au8’s application, with discussions ong...

A multinational team of researchers has proposed a new way of classifying Parkinson's disease (PD) that accounts for all the underlying complex biological processes involved in the progressive disorder. Led by Dr. Antony Lang, a neurologist, a senior scientist at Krembil Brain Institute and a...

Significant improvements in both vision and cognition, sustained over three years, were reported with CNM-Au8 treatment in results from the long-term open-label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis Michael Barnett, a ...

A massive cache of ancient genomes has helped researchers trace the origins of a wide variety of the genetic traits that occur in modern Europeans. According to the ancient DNA, characteristics such as an increased risk of developing multiple sclerosis may have reached Europe more than 45,000 ...

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including ...

Long-term CNM-Au8 treatment demonstrated improvement of vision as measured by low contrast visual acuity (LCLA), an assessment of visual function in people living with multiple sclerosis (MS), through 35 months from randomization, p<0.0001 Long-term CNM-Au8 treatment demonstrated improveme...